Search results
Enspectra receives breakthrough status for AI-powered skin imaging platform
Medical Device Network via Yahoo Finance· 1 day agoThe imaging platform is aimed at evaluating lesions indicative of basal cell carcinoma (BCC) and ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 3 hours agoThe companies are also testing the combo in patients with melanoma, non-small cell lung cancer,...
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab,...
The Pilot News· 6 days agoSugemalimab is expected to become the first anti-PD-L1 monoclonal antibody (mAb) in the world approved in Europe for both first-line squamous and non-squamous< ...
..., in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous ...
Digital Journal· 4 days ago"It is encouraging that IFx-2.0 demonstrated the ability to overcome resistance to ICI in 63% of patients with advanced MCC, even in patients who progressed on both anti-PD1 therapy followed ...
Replimune (REPL) Gains on Positive Data From Melanoma Study
Zacks via Yahoo Finance· 3 hours agoReplimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall...
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Pharmaceutical Technology via Yahoo Finance· 4 days ago“The CHMP recommendation brings us closer to delivering this innovative treatment to European...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via Yahoo Finance· 4 days agoMonday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of...
How to Spot Skin Cancer on the Scalp (Hint: Your Hair Stylist Can Help) + 4 Ways To Cut Your Risk
Woman's World via Yahoo News· 4 days agoBasal cell carcinoma may look like a pink or fleshy bump, while squamous cell carcinoma typically...
An mRNA Melanoma Vaccine Shows Promise
Time via Yahoo News· 7 days agoEach...vaccine includes up to 34 tumor-specific targets, and most patients generated strong T cell populations against 15 to 20 of them. “We are hitting...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoFlamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC) PR Newswire ...
